Rossari Biotech (ROSSARI) Aandelenoverzicht
Rossari Biotech Limited houdt zich bezig met de productie en verkoop van speciale chemicaliën in India en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
ROSSARI Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rossari Biotech Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹527.10 |
| 52 Week Hoogtepunt | ₹766.00 |
| 52 Week Laag | ₹375.00 |
| Bèta | 0.53 |
| 1 maand verandering | 0.95% |
| 3 maanden verandering | 23.13% |
| 1 Jaar Verandering | -21.36% |
| 3 jaar verandering | -37.48% |
| 5 jaar verandering | -55.05% |
| Verandering sinds IPO | -28.93% |
Recent nieuws en updates
Narratiefupdate • Jun 30
ROSSARI: New R&D Relocation Will Support Stronger Long-Term Prospects
Analysts have reduced their fair value estimate for Rossari Biotech from ₹813 to ₹637. This change reflects an updated view that combines a slightly lower discount rate and higher projected revenue growth with expectations of a lower profit margin and a reduced future P/E multiple.
Narratiefupdate • Jun 16
ROSSARI: Navi Mumbai R And D Shift Will Drive Future Upside
Analysts have kept Rossari Biotech's fair value estimate steady at ₹601.75, with only minor adjustments to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially change their overall valuation view. What's in the News Board meeting scheduled for May 27, 2026, at 16:00 IST to consider the re appointment of Ms. Esha Padmanabhan Achan as a Non Executive Independent Director and the grant of options under the Rossari Employee Stock Option Plan 2019.Narratiefupdate • Jun 01
ROSSARI: New Navi Mumbai R And D Move Will Support Future Upside
Analysts have maintained their fair value estimate for Rossari Biotech at ₹601.75, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, resulting in an unchanged price target. What's in the News A board meeting is scheduled for May 27, 2026 at 16:00 IST to consider the reappointment of Ms. Esha Padmanabhan Achan as a non-executive independent director and to evaluate the grant of options under the Rossari Employee Stock Option Plan 2019.Narratiefupdate • May 14
ROSSARI: New R&D Consolidation And Board Decisions Will Drive Future Upside
Analysts now set a revised price target for Rossari Biotech at ₹601.75, down from ₹635.50, reflecting slightly softer assumptions around revenue growth, profit margins, and future P/E multiples. What's in the News Rossari Biotech has set up a new Research and Development Facility at Ellora Olearise, A-786, 06th Floor, Khairane MIDC, Koparkhairane, Navi Mumbai 400 710.Analyseartikel • May 04
Rossari Biotech's (NSE:ROSSARI) Profits Appear To Have Quality Issues
Rossari Biotech Limited's ( NSE:ROSSARI ) stock didn't jump after it announced some healthy earnings. We did some...Recent updates
Narratiefupdate • Jun 30
ROSSARI: New R&D Relocation Will Support Stronger Long-Term Prospects
Analysts have reduced their fair value estimate for Rossari Biotech from ₹813 to ₹637. This change reflects an updated view that combines a slightly lower discount rate and higher projected revenue growth with expectations of a lower profit margin and a reduced future P/E multiple.Narratiefupdate • Jun 16
ROSSARI: Navi Mumbai R And D Shift Will Drive Future Upside
Analysts have kept Rossari Biotech's fair value estimate steady at ₹601.75, with only minor adjustments to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially change their overall valuation view. What's in the News Board meeting scheduled for May 27, 2026, at 16:00 IST to consider the re appointment of Ms. Esha Padmanabhan Achan as a Non Executive Independent Director and the grant of options under the Rossari Employee Stock Option Plan 2019.Narratiefupdate • Jun 01
ROSSARI: New Navi Mumbai R And D Move Will Support Future Upside
Analysts have maintained their fair value estimate for Rossari Biotech at ₹601.75, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, resulting in an unchanged price target. What's in the News A board meeting is scheduled for May 27, 2026 at 16:00 IST to consider the reappointment of Ms. Esha Padmanabhan Achan as a non-executive independent director and to evaluate the grant of options under the Rossari Employee Stock Option Plan 2019.Narratiefupdate • May 14
ROSSARI: New R&D Consolidation And Board Decisions Will Drive Future Upside
Analysts now set a revised price target for Rossari Biotech at ₹601.75, down from ₹635.50, reflecting slightly softer assumptions around revenue growth, profit margins, and future P/E multiples. What's in the News Rossari Biotech has set up a new Research and Development Facility at Ellora Olearise, A-786, 06th Floor, Khairane MIDC, Koparkhairane, Navi Mumbai 400 710.Analyseartikel • May 04
Rossari Biotech's (NSE:ROSSARI) Profits Appear To Have Quality Issues
Rossari Biotech Limited's ( NSE:ROSSARI ) stock didn't jump after it announced some healthy earnings. We did some...Narratiefupdate • Apr 25
ROSSARI: Upcoming Board Meeting And Dividend Decision Will Shape Future Upside Potential
Analysts have kept Rossari Biotech's fair value estimate steady at ₹635.5, with only small technical tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, so the headline price target remains unchanged. What's in the News Board meeting scheduled for April 27, 2026, to review and approve audited standalone and consolidated financial statements for the quarter and financial year ended March 31, 2026 (company filing).Narratiefupdate • Apr 09
ROSSARI: Greenfield Expansion And Subsidiary Restructuring Will Shape Future Upside Potential
Analysts have kept Rossari Biotech's fair value estimate steady at ₹635.50, citing only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions rather than any major shift in the core outlook. What's in the News A board meeting is scheduled on January 17, 2026 at 12:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narratiefupdate • Mar 26
ROSSARI: Greenfield Capacity Expansion Will Support Future Upside Potential
Analysts have maintained the fair value estimate for Rossari Biotech at ₹635.5, making only minor technical adjustments to assumptions such as the discount rate, revenue growth, profit margin, and future P/E, which result in an essentially unchanged price target view. What's in the News A board meeting is scheduled for January 17, 2026, at 12:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narratiefupdate • Mar 08
ROSSARI: Greenfield Expansion And Subsidiary Buildout Will Support Future Upside
Analysts have maintained Rossari Biotech's fair value estimate at ₹635.50, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E to reflect updated modelling assumptions rather than a change in conviction. What's in the News A board meeting is scheduled on Jan 17, 2026 at 12:30 Indian Standard Time to consider unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Narratiefupdate • Feb 22
ROSSARI: Greenfield Capacity Expansion Will Support Future Upside Potential
Analysts have kept their fair value estimate for Rossari Biotech steady at ₹635.5, with the unchanged price target reflecting only marginal tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Board meeting scheduled for January 17, 2026, to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider several key corporate actions, including new projects and asset changes (company filing).Narratiefupdate • Feb 05
ROSSARI: Greenfield Expansion And Subsidiary Reshaping Will Support Future Upside Potential
Analysts have trimmed their fair value estimate for Rossari Biotech slightly from ₹637.33 to ₹635.50, reflecting updated assumptions around discount rate, profit margin and future P/E, while keeping revenue growth expectations broadly aligned with prior views. What's in the News Board meeting scheduled on Jan 17, 2026 at 12:30 IST to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, and to consider several corporate actions (company filing).Narratiefupdate • Jan 22
ROSSARI: International Capacity Expansion Plans Will Drive Future Upside Potential
Analysts have revised their price target on Rossari Biotech lower from ₹795.75 to about ₹637.33, citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. What's in the News A board meeting is scheduled on Jan 17, 2026, to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Analyseartikel • Jan 22
Analysts Have Lowered Expectations For Rossari Biotech Limited (NSE:ROSSARI) After Its Latest Results
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...Narratiefupdate • Jan 08
ROSSARI: International Capacity Expansions Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Rossari Biotech steady at ₹795.75, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E to better reflect current expectations. What's in the News A board meeting is scheduled on December 18, 2025 at 10:30 a.m. Indian Standard Time to consider and approve the incorporation of a wholly owned subsidiary in the Republic of Singapore (company filing).Narratiefupdate • Dec 21
ROSSARI: Planned Singapore Subsidiary Will Drive Future International Expansion Upside
Analysts have reaffirmed their price target on Rossari Biotech at ₹795.75 per share, with only marginal tweaks to underlying assumptions such as discount rate, long term revenue growth, profit margin, and future P E multiple, reflecting a largely unchanged outlook on the company’s earnings trajectory and risk profile. What's in the News Board to meet on December 18, 2025, to consider incorporating a wholly owned subsidiary in the Republic of Singapore (Board Meeting) Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility, taking total installed capacity to 1,52,500 MTPA (Business Expansions) Commissioned 15,000 MTPA ethoxylation capacity at Unitop in Phase 1 of a 30,000 MTPA plan, with Phase 2 expected by the third quarter of fiscal 2026 (Business Expansions) Board approved an investment of up to USD 8 million in Rossari International Limited Company in Saudi Arabia to evaluate and assess expansion plans in international markets (Business Expansions) Board meeting scheduled on October 15, 2025, to approve unaudited financial results for the quarter and half year ended September 30, 2025 (Board Meeting) Valuation Changes The consensus analyst price target remains unchanged at ₹795.75 per share, indicating a stable fair value assessment.Narratiefupdate • Dec 06
ROSSARI: Capacity Expansion And Saudi Subsidiary Investment Will Drive Future Upside
Narrative Update on Rossari Biotech Analysts have maintained their price target for Rossari Biotech at ₹795.75, citing largely unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples. Taken together, these factors suggest limited change in the company’s fundamental outlook.Narratiefupdate • Nov 22
ROSSARI: Additional Capacity Expansions Will Unlock Global Opportunities Ahead
Narrative Update on Rossari Biotech Analysts have maintained their fair value estimate for Rossari Biotech at ₹795.75, citing minimal changes in key financial assumptions and continued confidence in the company’s outlook. What's in the News Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility during the quarter, bringing total installed capacity to 1,52,500 MTPA.Narratiefupdate • Nov 04
ROSSARI: New Expansion Projects Will Drive Global Market Penetration
Narrative Update on Rossari Biotech: Analyst Price Target Revision Analysts have revised Rossari Biotech’s fair value estimate downward from ₹826.67 to ₹795.75, citing slightly lower expectations for revenue growth and profit margins. What's in the News The company commissioned an additional 20,000 MTPA capacity at its Dahej facility, bringing total installed capacity to 1,52,500 MTPA (Key Developments).Analyseartikel • Oct 28
We Think That There Are More Issues For Rossari Biotech (NSE:ROSSARI) Than Just Sluggish Earnings
Rossari Biotech Limited's ( NSE:ROSSARI ) recent weak earnings report didn't cause a big stock movement. Our analysis...Analyseartikel • Jun 24
Here's Why Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights Rossari Biotech will host its Annual General Meeting on 30th of June Total pay for CEO Sunil Chari...
Nieuw narratief • Feb 10
Eco-friendly Solutions And New Capacities Will Strengthen Future Prospects
Strategic investments in capacity expansion and innovation in eco-friendly solutions are expected to drive revenue growth in domestic and international markets.Analyseartikel • Aug 17
Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All
Key Insights Rossari Biotech's Annual General Meeting to take place on 23rd of August Salary of ₹12.1m is part of CEO...Analyseartikel • Jun 14
Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • May 07
Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals
Investors were disappointed with Rossari Biotech Limited's ( NSE:ROSSARI ) earnings, despite the strong profit numbers...Analyseartikel • May 03
Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report
Last week, you might have seen that Rossari Biotech Limited ( NSE:ROSSARI ) released its full-year result to the...Analyseartikel • Feb 10
One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically
The analyst covering Rossari Biotech Limited ( NSE:ROSSARI ) delivered a dose of negativity to shareholders today, by...Analyseartikel • Sep 23
Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture
What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...Analyseartikel • Apr 06
Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analyseartikel • Feb 19
Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues
Rossari Biotech Limited ( NSE:ROSSARI ) shareholders will have a reason to smile today, with the analysts making...Analyseartikel • Feb 17
Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...Analyseartikel • Feb 10
I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Analyseartikel • Nov 24
Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analyseartikel • Oct 12
With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Rendement voor aandeelhouders
| ROSSARI | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | -1.9% | -0.7% | -0.3% |
| 1Y | -21.4% | -5.9% | -2.8% |
Rendement versus industrie: ROSSARI presteerde slechter dan de Indian Chemicals -sector, die het afgelopen jaar een rendement van -5.9 % opleverde.
Rendement versus markt: ROSSARI presteerde slechter dan Indian Market, dat het afgelopen jaar een rendement van -2.8 % opleverde.
Prijsvolatiliteit
| ROSSARI volatility | |
|---|---|
| ROSSARI Average Weekly Movement | 6.6% |
| Chemicals Industry Average Movement | 6.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.2% |
Stabiele aandelenkoers: ROSSARI heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Indian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van ROSSARI is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1997 | 585 | Sunil Chari | www.rossari.com |
Rossari Biotech Limited houdt zich bezig met de productie en verkoop van speciale chemicaliën in India en daarbuiten. Het bedrijf biedt zeep en wasmiddelen, inkt, verf en coatings, keramiek en tegels, pulp en papier, cement, hoogwaardige additieven en waterzuiveringsoplossingen. Het bedrijf levert ook speciale textielchemicaliën, zoals katoen, polyester, acryl, wol, zijde, nylon, functionele afwerkingen, denim, drukwerk en duurzame oplossingen; en verzorgingsproducten voor huisdieren, waaronder natuurlijke shampoos, poeders, deodorants, sprays, crèmes en vloerspoelvloeistoffen onder de merknamen Lozalo, Hunger Fills en Sniffy.
Rossari Biotech Limited Samenvatting
| ROSSARI fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹29.10b |
| Inkomsten(TTM) | ₹1.49b |
| Inkomsten(TTM) | ₹23.96b |
19.6x
Koers/Winstverhouding1.2x
P/S-verhoudingIs ROSSARI overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ROSSARI resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹23.96b |
| Kosten van inkomsten | ₹16.77b |
| Brutowinst | ₹7.19b |
| Overige uitgaven | ₹5.70b |
| Inkomsten | ₹1.49b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 26.94 |
| Brutomarge | 30.00% |
| Nettowinstmarge | 6.23% |
| Schuld/Eigen Vermogen Verhouding | 30.6% |
Hoe presteerde ROSSARI op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.09%
Huidig dividendrendement2%
UitbetalingsratioBetaalt ROSSARI een betrouwbaar dividend?
Zie ROSSARI dividendgeschiedenis en benchmarks| Rossari Biotech dividenddata | |
|---|---|
| Ex Dividend Datum | Jul 10 2026 |
| Betaaldatum dividend | Aug 19 2026 |
| Dagen tot Ex-dividend | 8 days |
| Dagen tot dividendbetaaldatum | 48 days |
Betaalt ROSSARI een betrouwbaar dividend?
Zie ROSSARI dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/01 12:19 |
| Aandelenkoers aan het einde van de dag | 2026/07/01 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Rossari Biotech Limited wordt gevolgd door 5 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Nitesh Dhoot | Anand Rathi Shares and Stock Brokers Limited |
| Abhishek Navalgund | Centrum Broking Limited |